ZA200305326B - Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists. - Google Patents

Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists.

Info

Publication number
ZA200305326B
ZA200305326B ZA200305326A ZA200305326A ZA200305326B ZA 200305326 B ZA200305326 B ZA 200305326B ZA 200305326 A ZA200305326 A ZA 200305326A ZA 200305326 A ZA200305326 A ZA 200305326A ZA 200305326 B ZA200305326 B ZA 200305326B
Authority
ZA
South Africa
Prior art keywords
dementia
treatment
neurodegenerative diseases
lhrh antagonists
intermediate doses
Prior art date
Application number
ZA200305326A
Other languages
English (en)
Inventor
Juergen Engel
Rainer Voegeli
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of ZA200305326B publication Critical patent/ZA200305326B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
ZA200305326A 2001-04-30 2003-07-10 Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists. ZA200305326B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28743401P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
ZA200305326B true ZA200305326B (en) 2003-07-30

Family

ID=23102886

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200305326A ZA200305326B (en) 2001-04-30 2003-07-10 Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists.

Country Status (28)

Country Link
US (1) US7288517B2 (fr)
EP (1) EP1392348B1 (fr)
JP (1) JP2004529207A (fr)
KR (1) KR20040000446A (fr)
CN (1) CN1317030C (fr)
AT (1) ATE400287T1 (fr)
AU (1) AU2002310788B2 (fr)
BG (1) BG108339A (fr)
BR (1) BR0209290A (fr)
CA (1) CA2444876A1 (fr)
CZ (1) CZ20033167A3 (fr)
DE (1) DE60227507D1 (fr)
DK (1) DK1392348T3 (fr)
ES (1) ES2307760T3 (fr)
HK (1) HK1072000A1 (fr)
HU (1) HUP0400067A2 (fr)
IL (1) IL156777A0 (fr)
MX (1) MXPA03008666A (fr)
NO (1) NO20034322D0 (fr)
NZ (1) NZ544417A (fr)
PL (1) PL362319A1 (fr)
PT (1) PT1392348E (fr)
RU (1) RU2319501C2 (fr)
SI (1) SI1392348T1 (fr)
SK (1) SK14512003A3 (fr)
UA (1) UA80679C2 (fr)
WO (1) WO2002102401A1 (fr)
ZA (1) ZA200305326B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
ES2261437T3 (es) 2000-07-05 2006-11-16 Astellas Pharma Inc. Derivados de propano-1,3-diona.
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
WO2005118556A1 (fr) * 2004-06-04 2005-12-15 Astellas Pharma Inc. Dérivé de propane-1,de 3-dione ou son sel
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
WO2006071274A2 (fr) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Acetate de leuprolide et inhibiteurs de l'acetylcholinesterase ou antagonistes des recepteurs nmda pour le traitement de la maladie d'alzheimer
CA2603185C (fr) 2005-03-31 2011-07-26 Astellas Pharma Inc. Derive de propane-1,3-dione ou sel de celui-ci
JP5406030B2 (ja) * 2006-10-21 2014-02-05 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ３阻害薬としての使用
US20100190722A1 (en) * 2007-09-11 2010-07-29 Dorian Bevec Substance p and thyrotropin releasing hormone for therapeutic applications
AU2008297899A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of human neuropeptide as a therapeutic agent
EP2095818A1 (fr) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Utilisation d'antagonistes LHRH dans des doses n'impliquant pas de castration
US20110129532A1 (en) * 2008-05-29 2011-06-02 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
MX336726B (es) 2010-09-27 2016-01-27 Abbott Gmbh & Co Kg Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3560555A1 (fr) * 2018-04-26 2019-10-30 LifeArc Composition pour traiter une ou plusieurs maladies liées aux strogènes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
JP2000511532A (ja) * 1996-05-20 2000-09-05 メルク エンド カンパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモンのアンタゴニスト
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
NZ515460A (en) * 1999-05-14 2004-06-25 Neurocrine Biosciences Inc Imidazo- and pyrrolo[1,2-A]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
CA2309395A1 (fr) * 1999-06-04 2000-12-04 Richard Lloyd Bowen Methodes de prevention et de traitement de la maladie d'alzheimer
DE60022769T2 (de) 1999-10-15 2006-07-06 Neurocrine Biosciences, Inc., San Diego Gonadotropin freisetzenden hormon rezeptor antagonisten und ihre verwandten verwendungen
CA2406832A1 (fr) 2000-04-13 2002-10-10 Takeda Chemical Industries, Ltd. Agents preventifs/remedes pour la maladie d'alzheimer
ES2261437T3 (es) * 2000-07-05 2006-11-16 Astellas Pharma Inc. Derivados de propano-1,3-diona.

Also Published As

Publication number Publication date
DE60227507D1 (de) 2008-08-21
KR20040000446A (ko) 2004-01-03
HK1072000A1 (en) 2005-08-12
CZ20033167A3 (cs) 2004-08-18
RU2003134949A (ru) 2005-02-10
EP1392348A1 (fr) 2004-03-03
UA80679C2 (en) 2007-10-25
JP2004529207A (ja) 2004-09-24
ATE400287T1 (de) 2008-07-15
NO20034322L (no) 2003-09-26
MXPA03008666A (es) 2004-10-15
NO20034322D0 (no) 2003-09-26
BG108339A (bg) 2004-11-30
HUP0400067A2 (hu) 2004-04-28
NZ544417A (en) 2008-03-28
DK1392348T3 (da) 2008-09-29
AU2002310788B2 (en) 2007-04-05
SK14512003A3 (sk) 2004-08-03
EP1392348B1 (fr) 2008-07-09
CN1575185A (zh) 2005-02-02
CA2444876A1 (fr) 2002-12-27
SI1392348T1 (sl) 2008-12-31
US20020177556A1 (en) 2002-11-28
ES2307760T3 (es) 2008-12-01
BR0209290A (pt) 2004-07-13
RU2319501C2 (ru) 2008-03-20
CN1317030C (zh) 2007-05-23
US7288517B2 (en) 2007-10-30
WO2002102401A1 (fr) 2002-12-27
PL362319A1 (en) 2004-10-18
PT1392348E (pt) 2008-09-09
IL156777A0 (en) 2004-02-08

Similar Documents

Publication Publication Date Title
HK1072000A1 (en) Treatment of alzheimer's diseases with intemediatedoses of lhrh antagonists
MY134906A (en) Prevention and treatment of amyloidogenic disease
IL149924A0 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
LU92855I2 (fr) Combinaison de rilpivirine ou une forme thérapeutique equivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, ténofovir, en particulier le fumarate de ténofovir disoproxil, et l'emtricitabine
MXPA02011621A (es) Mimeticos de trombopoyetina.
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
GB0223040D0 (en) Therapeutic compounds
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
JO2207B1 (en) Pharmaceutical radiological compounds to diagnose Alzheimer's disease
EA200400352A1 (ru) Органолептически приемлемые распадающиеся во рту композиции
MY124786A (en) Bis-arylsulfones
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
WO2003053136A3 (fr) Modele de souris triplement transgenique de la maladie d'alzheimer
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
WO2002062383A3 (fr) Nouvelle methode de traitement
MXPA03011502A (es) Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.
MXPA04000870A (es) Uso de antagonistas-lhrh para mejorar la inmunidad mediada por celula-t.
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
PL377110A1 (pl) Zapobieganie i leczenie choroby Alzheimera
MXPA03008406A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina.
WO2003000269A3 (fr) Nouvelle utilisation d'inhibiteurs de pde 10a
AU2002312797A1 (en) Peptide for the diagnosis and therapy of alzheimer's disease